Drug updated on 11/15/2023
| Dosage Form | Injection (intravenous; 9.5 mg) |
| Drug Class | Cyclic pyranopterin monophosphates |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Nulibry (fosdenopterin) Prescribing Information. | 2022 | Alcami Carolinas Corporation, Charleston, SC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Nulibry. | 2022 | EMA |